Status and phase
Conditions
Treatments
About
A pharmacodynamic study to evaluate the effect of AV-299 on exploratory pharmacodynamic markers in subjects with advanced solid tumors who have liver metastases.
To evaluate safety and tolerability of AV-299 administered IV in subjects with advanced solid tumors who have liver metastases.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Note: Additional tumor histologies may be eligible based on available HGF/c-Met pathway data and approval by the Sponsor.
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
19 participants in 1 patient group
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal